Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Hsieh

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Journal of Medical Economics|September 16, 2025
Assessment of unmet clinical needs and healthcare resource use among statin-treated patients with or at risk of developing atherosclerotic cardiovascular diseaseNancy Ortiz, Jacqueline Shehata, Jeremy Smart, et al.
Journal of Clinical Lipidology|May 23, 2018
The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS studyMichael Davidson, Michael Stevenson, Andrew Hsieh, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 24, 2024
Raman spectroscopy for monitoring free sulfhydryl formation during monoclonal antibody manufacturingZhenshu Wang, Andrew Hsieh, Patricia Rose, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 26, 2025
A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy VolunteersJohn J P Kastelein, Marc Ditmarsch, Andrew Hsieh, et al.
American Journal of Preventive Cardiology|April 20, 2026
The emerging role of CETP inhibition in the prevention of Alzheimer's diseaseMichael H Davidson, Andrew Hsieh, Mathijs de Kleer, et al.
European Heart Journal|May 25, 2026
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trialsStephen J Nicholls, Adam J Nelson, Kausik K Ray, et al.
Journal of Clinical Pharmacology|August 19, 2024
A Randomized, Parallel, Open-Label, Single-Dose and Multiple-Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in ChinaJing Zhang, Guoying Cao, Yong Huo, et al.
Pharmacology Research & Perspectives|October 19, 2024
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trialsStephen J Nicholls, Adam J Nelson, John J P Kastelein, et al.
Journal of the American College of Cardiology|September 1, 2025
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled AnalysisStephen J Nicholls, Adam J Nelson, Kausik K Ray, et al.
American Journal of Preventive Cardiology|June 15, 2026
Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trialsLiffert Vogt, Michael H Davidson, Michael Szarek, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Journal of Medical Economics|September 16, 2025
Assessment of unmet clinical needs and healthcare resource use among statin-treated patients with or at risk of developing atherosclerotic cardiovascular diseaseNancy Ortiz, Jacqueline Shehata, Jeremy Smart, et al.
Journal of Clinical Lipidology|May 23, 2018
The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS studyMichael Davidson, Michael Stevenson, Andrew Hsieh, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 24, 2024
Raman spectroscopy for monitoring free sulfhydryl formation during monoclonal antibody manufacturingZhenshu Wang, Andrew Hsieh, Patricia Rose, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 26, 2025
A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy VolunteersJohn J P Kastelein, Marc Ditmarsch, Andrew Hsieh, et al.
American Journal of Preventive Cardiology|April 20, 2026
The emerging role of CETP inhibition in the prevention of Alzheimer's diseaseMichael H Davidson, Andrew Hsieh, Mathijs de Kleer, et al.
European Heart Journal|May 25, 2026
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trialsStephen J Nicholls, Adam J Nelson, Kausik K Ray, et al.
Journal of Clinical Pharmacology|August 19, 2024
A Randomized, Parallel, Open-Label, Single-Dose and Multiple-Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in ChinaJing Zhang, Guoying Cao, Yong Huo, et al.
Pharmacology Research & Perspectives|October 19, 2024
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trialsStephen J Nicholls, Adam J Nelson, John J P Kastelein, et al.
Journal of the American College of Cardiology|September 1, 2025
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled AnalysisStephen J Nicholls, Adam J Nelson, Kausik K Ray, et al.
American Journal of Preventive Cardiology|June 15, 2026
Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trialsLiffert Vogt, Michael H Davidson, Michael Szarek, et al.
Pageof 4